Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment.
about
Ports and complications for intraperitoneal chemotherapy deliveryVersatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer.A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.Novel Intraperitoneal Treatment With Non-Thermal Plasma-Activated Medium Inhibits Metastatic Potential of Ovarian Cancer CellsHematogenous metastasis of ovarian cancer: rethinking mode of spread.Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts.Proteomics and ovarian cancer: integrating proteomics information into clinical careLaparoscopy-assisted supracervical hysterectomy for ovarian cancer: cervical recurrence.Intraperitoneal therapy for peritoneal cancer.Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancerConsolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.Ex vivo culture of primary human fallopian tube epithelial cells.A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic studyHyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors.Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer.Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer modelImpact of vessel maturation on antiangiogenic therapy in ovarian cancer.Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin.Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer.Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamicsOffice-based intraperitoneal chemotherapy for ovarian cancer.Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients.Therapeutic strategies based on polymeric microparticles.Intraperitoneal chemotherapy: rationale, applications, and limitations.Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey.Frontline treatment of epithelial ovarian cancer.Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis.Intraperitoneal paclitaxel induces regression of peritoneal metastasis partly by destruction of peripheral microvessels.Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer.Reducing excessive toxicity in ovarian cancer treatment: a personalized approach.Intraperitoneal distribution imaging in ovarian cancer patients.Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial.Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer.Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals.Ovarian cancer survival: steady improvement, despite rhetoric to the contrary.Ovarian cancer: a brief historical overview of intraperitoneal trials.
P2860
Q26822458-86E79145-B946-4270-9525-5180D04243F8Q27687617-324953CB-21AB-4301-9750-3FC64D1E08DDQ30299971-248DA215-DCD4-4DEF-BAB7-C29371D91FADQ33470931-ABEE9627-002B-43EA-97B7-D69577276ADEQ33908024-EBA1DD28-D710-4632-BA6C-31B8DE3D243DQ33976557-465728C6-20B5-49DE-961A-F88E8542E0A6Q34126627-2D274AC3-B517-4DE6-BBBA-4F674A8A5AB4Q34132518-5D04A7FD-99E4-4562-8098-5CD1743FF61DQ34789701-34D68295-E2E4-4753-872F-76CE5AAFEE65Q35114915-88A0CEDE-1712-4462-8F83-BDD28F490C4DQ35154140-A0101601-046E-4FE9-9170-C1327FAEA974Q35392397-E411D322-22B9-42CE-9175-F36D7766BEBFQ35627284-08B0CBD5-9F25-4901-A716-13D4930A37C7Q35739551-099DB051-C0CF-4EA3-A051-6D914C1BD210Q35869447-82D82B59-EEBE-4582-936A-B5D59576AA85Q35886105-E374A52E-889A-4376-A2DB-2E263D0DF225Q36073949-C6F98DD6-DCB5-4796-A1F2-6D8C24803498Q36593708-01861EF4-C952-42B8-A31E-0431CC67330DQ37101337-009113CE-34EB-4304-A03F-4496A4174D63Q37202777-CAB0DF71-CD05-4C7B-8C33-8FE58485B70AQ37230288-2960193B-B561-4B82-8951-7421F8436FFEQ37415227-6D0B2588-EABC-4503-9A76-2A23C7230B90Q37435420-33FC7F4F-BD68-4026-98BF-A36031F6690DQ37477107-E43C6661-A9C0-4294-8033-2D92883F9D91Q37662806-0578012A-E2B0-44D8-9837-01B1B5C170FBQ38016146-03066583-2B7D-47EF-8BE7-09137723A0B1Q38156120-B464682B-69C7-4C7D-B713-951D39CE7BD9Q38183786-3A35D022-4D00-4B6A-AD4A-96622708C937Q38213258-C42FCBB0-CCEF-4F16-B215-19D36C5D6311Q38669746-581C5F77-6E36-4FD2-8F54-D3667A481D4AQ38800565-9F5F1285-814E-4A2C-9F05-D1AC703536E4Q39030522-78DE1313-2376-4921-8B44-57154B6DB75CQ39120205-A58B4450-01DA-4A27-B008-06C8CD2BBD29Q39739012-9B5EFE6A-7EFA-49C0-989C-44097161CAC9Q39936525-3FA74D6F-150E-46C6-A0C8-E5083EBD2187Q39995266-98C15189-51B2-420E-9FBA-77CEE5CCB629Q41897007-79D2BA3F-0924-411D-8BF5-EE64F0BF44B2Q42321339-4558648A-E7B7-4B81-BA1E-0CEC72E96A5BQ43883988-692C43EA-FFD8-44F8-A3B7-1A6B86BBD7A2Q48159781-603F90CF-A385-4811-BA68-3C52634753CC
P2860
Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Intraperitoneal chemotherapy o ...... ractical aspects of treatment.
@ast
Intraperitoneal chemotherapy o ...... ractical aspects of treatment.
@en
type
label
Intraperitoneal chemotherapy o ...... ractical aspects of treatment.
@ast
Intraperitoneal chemotherapy o ...... ractical aspects of treatment.
@en
prefLabel
Intraperitoneal chemotherapy o ...... ractical aspects of treatment.
@ast
Intraperitoneal chemotherapy o ...... ractical aspects of treatment.
@en
P356
P1476
Intraperitoneal chemotherapy o ...... ractical aspects of treatment.
@en
P2093
Joan L Walker
Maurie Markman
P304
P356
10.1200/JCO.2005.05.2456
P407
P577
2006-02-06T00:00:00Z